SEC Filing Summary

This filing details a transaction involving Edward Pershing, CEO of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), who acquired an 8% Unsecured Convertible Promissory Note with a principal value of $15,000. The note is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share. The Series D-1 Preferred Stock is further convertible into the Issuer's common stock at a 10:1 ratio. The conversion of the note is automatic 12 months after issuance, or can be elected voluntarily by the holder. The Series D-1 Preferred Stock will automatically convert into common stock on December 31, 2028, unless converted earlier. This transaction is reported on Form 4.